Top Industry Players in Medical Aesthetics Market -"Allergan and Cynosure"

Strategic analysis of the market developments between 2015 and 2018 revealed that growth strategies such as product launches, enhancements, and approvals; acquisitions; agreements, partnerships, and collaborations; and expansions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the medical aesthetics market. 

Among these business strategies, product launches, enhancements, and approvals and agreements, partnerships, and collaborations were the two most-widely adopted growth strategies.

The global medical aesthetics market is projected to reach USD 17.07 billion by 2023 from USD 10.30 billion in 2018, at a CAGR of 10.6% during the forecast period.

Allergan and Cynosure are leading players in Medical Aesthetics Market

Allergan (Ireland) held the leading position in the global facial aesthetics products market in 2017. The company has a broad product portfolio and focuses on continuous innovation and development of new products to sustain its market leadership. Over the past few years, the company enhanced its share in the market by introducing new products and securing approvals for various medical aesthetic products. 

Cynosure (a wholly owned subsidiary of Hologic, US) held the leading position in the global medical aesthetics market for energy & light-based devices in 2017. Cynosure is a prominent manufacturer of laser-based medical aesthetic devices. In 2017, Hologic acquired Cynosure, which helped Hologic to enter the medical aesthetics market. Cynosure has a strong patent portfolio of 37 US patents, and it markets around 14 light/laser-based systems for medical aesthetic applications. 

To Know More, Download FREE Brochure @
https://tinyurl.com/y2qnlo7a

Parkinson’s Disease Treatment Market 2019 Rapidly Growing to Hits $5.69 billion in 2022

Parkinson’s disease treatment is used to treat the symptoms of Parkinson’s disease, generally, medication is the first line treatment for this disease. 

The global Parkinson’s disease treatment market is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1%. Rising geriatric population and government funding for research on Parkinson’s disease are the driving factors for this market.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247

The Parkinson’s disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region

"Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022"

Currently, a wide range of treatments is available for alleviating the symptoms of Parkinson’s disease. Medication is the first line therapy for treating the disease; however, they are not effective in all stages of the disease. 

In the severe stages, medications do not show pharmacological action in relieving disease symptoms. Neurologists perform thalamotomy, pallidotomy, or implant deep brain stimulation (DBS) devices in order to ease symptoms.

Target Audience for this Report:

• Parkinson’s disease treatment product manufacturers
• Parkinson’s disease treatment dealers and suppliers
• Human identification service providers
• Parkinson’s disease associations
• Academic institutions
• Venture capitalists
• Consulting firms

To Know More @ https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html